DV1098Z
Brachytherapy Prostate to None with Iridium 192 (Ir-192), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | V Male Reproductive System |
| Operation | 1 Brachytherapy |
| Body Part | 0 Prostate |
| Approach | 9 High Dose Rate (HDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the male reproductive system involves placing radioactive sources, most often tiny seeds, directly into or immediately next to the prostate gland so the radiation dose is concentrated at very close range while tissue farther away receives comparatively little exposure. Low-dose-rate implants are typically permanent, with the seeds left in place indefinitely as their radioactivity decays over weeks to months, while high-dose-rate brachytherapy uses temporary catheters that deliver a strong dose over a short session and are then removed. It is used primarily for localized prostate cancer, either alone for lower-risk disease or combined with external beam radiation for higher-risk cases.
The procedure is performed under image guidance, usually transrectal ultrasound, with the patient under anesthesia while the physician positions needles or catheters to place the sources precisely.
Anatomy & Axis Detail
Prostate
Brachytherapy of the prostate involves placing radioactive sources directly into the gland, either as permanent low-dose-rate seeds or temporary high-dose-rate catheters, taking advantage of the prostate's fixed, accessible position between the bladder and rectum for transperineal implantation under image guidance. This technique allows a highly concentrated dose to be delivered to the gland itself while limiting exposure to the adjacent rectal wall and urethra compared to purely external approaches, making it a common option for localized, lower-risk prostate cancer either alone or combined with external beam therapy. Because seed or catheter placement requires precise mapping of prostate volume and urethral course, transrectal ultrasound or MRI guidance is typically used during the procedure. Patients receiving permanent seed implants require specific radiation safety counseling given the retained source material, a consideration unique to this delivery method at this body part.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
The coder must confirm from the procedure note whether the source is temporary (high-dose-rate afterloading) or permanent (low-dose-rate seed implant), since documentation of "seed implant" versus "HDR brachytherapy" affects the qualifier even though the root operation is the same. Physician documentation of the isotope used (such as iodine-125 or palladium-103 for permanent seeds) helps confirm the approach was brachytherapy rather than another modality. A common error is coding the diagnostic ultrasound guidance or the separate anesthesia encounter as part of the radiation procedure itself rather than coding only the source placement.